GlassScriptPhysician profile
Thomas W Lucas
NPI 1568411411
$22,655.82
in general payments reported to CMS, 2019-2025
38 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,112 · 2020: $2,335 · 2021: $4,345 · 2022: $1,857 · 2023: $2,813 · 2024: $2,211 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,857 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,857.02 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $6,229.59 | 2019-2022 | |
| Validus Pharmaceuticals LLC | $3,919.82 | 2020-2025 | Equetro, Equetro, Raldesy |
| Otsuka America Pharmaceutical, INC. | $1,568.51 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,267.65 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $931.15 | 2019-2025 | Rexulti, Brintellix |
| Abbvie INC. | $927.67 | 2021-2025 | |
| Corium, LLC | $808.11 | 2022-2025 | Azstarys, Azstarys |
| Alkermes, INC. | $761.71 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $659.13 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $598.88 | 2019-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $536.64 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $521.77 | 2019-2024 | Trintellix |
| Almatica Pharma LLC | $410.91 | 2022-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $387.37 | 2022-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $334.99 | 2019-2023 | Belsomra |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $321.75 | 2019-2025 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $277.15 | 2023-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $271.59 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $259.03 | 2022-2024 | Quviviq |
| Acadia Pharmaceuticals INC | $220.31 | 2021-2024 | Nuplazid |
| Tris Pharma INC | $207.83 | 2019-2023 | Dyanavel Xr |
| Eisai INC. | $151.31 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $147.99 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $115.04 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $113.93 | 2019 | |
| Lilly USA, LLC | $113.48 | 2024-2025 | Kisunla, Zepbound |
| Allergan, INC. | $108.66 | 2019-2020 | |
| Bausch Health US, LLC | $94.98 | 2023-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $74.13 | 2023 | Secuado |
| Livanova USA, INC. | $64.90 | 2020-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Arbor Pharmaceuticals, INC. | $60.79 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $49.60 | 2019-2023 | Jornay Pm |
| Harmony Biosciences LLC | $36.10 | 2021-2024 | |
| Aytu Biopharma, INC. | $25.46 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.74 | 2025 | Rejoyn |
| Azurity Pharmaceuticals, INC. | $23.64 | 2023 | Horizant |
| Adlon Therapeutics L.P. | $15.40 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.11 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.